Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer

Celestia Higano, MD
Published: Thursday, Aug 31, 2017



Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.

Approximately one-quarter of patients with metastatic prostate cancer have DNA-damaged alterations, states Higano. PARP inhibitors are a different treatment paradigm for prostate cancer that have shown to be effective in this patient population.
 
SELECTED
LANGUAGE


Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.

Approximately one-quarter of patients with metastatic prostate cancer have DNA-damaged alterations, states Higano. PARP inhibitors are a different treatment paradigm for prostate cancer that have shown to be effective in this patient population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x